Duration of isolation and contagiousness in coronavirus disease 2019 (COVID-19) patients receiving tocilizumab and dexamethasone: A case series

Infect Control Hosp Epidemiol. 2023 Apr;44(4):655-658. doi: 10.1017/ice.2022.14. Epub 2022 Feb 9.

Abstract

We describe 10 patients with severe coronavirus disease 2019 (COVID-19) who received tocilizumab and dexamethasone. We correlated isolation duration with cycle thresholds (Ct) values of nucleic acid amplification tests, clinical state and viral cultures. Isolation duration exceeded 21 days for 7 patients due to positive viral cultures or Ct values <30.

MeSH terms

  • COVID-19 Drug Treatment
  • COVID-19*
  • Dexamethasone
  • Humans
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • tocilizumab
  • Dexamethasone